Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Vinay Jahagirdar

Liver Transplant · Medical College of Virginia

View

Dr. Lauren Feld

Liver Transplant · UMass Memorial

View

Dr. Sonali Paul

Liver Transplant · UCMC

View

Dr. Pierre Gholam

Liver Transplant · CWRU

View

Dr. Elliot Tapper

Liver Transplant · UM

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View

Dr. Laura Sahyoun

IBD · WCM

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Financial burden among liver transplant candidates is associated with financial distress and work impairment: A U.S. multicenter study.

    Jun 29, 2026DOI: 10.1097/hc9.0000000000000985Journal ArticleHepatology Communications

    Written by: Elizabeth S AbyMelanie HundtJonathan RiceMike KrissKali ZhouLauren NephewSarah R LieberAlvaro Noriega RamirezBrett E FortuneClara TowPaola MejiaDeepika DevuniAnita KrisharaoShari RogalAlan NollStela CelajNathaly Cortez BazanPatricia JonesHersh ShroffKrista HuntAreej MazharDempsey HughesJackie B HensonLindsay Y KingThomas M LeventhalEnya ZhuGrace BizupLucinda LiMalia ArmstrongAnushka DalviLina NurhussienNora HorickChengbo ZengNneka N Ufere

    Find these authors on Roon

    NU
    Dr. Nneka Ufere
    Liver Transplant · MGH

    INTRODUCTION

    Chronic liver disease (CLD) is a growing public health concern in the United States (U.S.) with rising mortality, morbidity, and financial costs.1 In North America, the estimated prevalence of cirrhosis ranges from 300 to 1000 per 100,000 and has increased 1.5 to 2-fold in the past 2 decades.2,3 As cirrhosis rates climb, the demand for liver transplantation (LT) has grown accordingly, with a 71% increase in LT in the U.S. over the last decade.4 During this time, the age distribution of LT recipients shifted, with a notable increase in recipients aged 35–49 years. This subset of adults in their prime working years accounted for almost one-quarter of all LT recipients in 2023.4 Simultaneously, health care utilization and expenditure for CLD in the U.S. have grown dramatically, with average out-of-pocket (OOP) expenses for patients with CLD exceeding $19,000 in 2017.5–7Growing recognition of the substantial economic implications of CLD has prompted increased focus on the financial burden experienced by patients across several domains.8 Financial burden refers to the proportion of household income spent on healthcare costs. This includes both direct expenditures, such as out-of-pocket costs, and indirect costs, such as lost wages due to unemployment, reduced work productivity, and/or caregiving needs resulting in reduced household income.8 Financial burden can lead to financial distress, encompassing the maladaptive behavioral, material, and psychological coping mechanisms in response to high financial burden. In turn, financial distress can lead to financial toxicity, specifically worsened health outcomes [eg, health-related quality of life (HRQOL)]. Understanding these interconnected domains is essential for identifying at-risk patients and designing targeted interventions to reduce both financial and clinical consequences.Prior studies have demonstrated that high financial burden, and resultant financial distress and toxicity, are common among adult LT recipients.5,6,8–10 A multicenter study found that nearly one-quarter of LT recipients reported high financial burden, which was associated with medical debt and bankruptcy (material financial distress) and with higher daily activity impairment (financial toxicity).11 Similarly, behavioral indicators of financial distress, such as medication tradeoffs, have been linked to increased post-transplant hospital admissions. Employment outcomes further illustrate financial distress, with unemployment rates more than tripling post-transplant.11Despite these findings among adult LT recipients, data specific to financial burden, distress, and toxicity among adults undergoing LT evaluation remain limited. Existing studies are either single-center cross-sectional cohorts with limited generalizability or large database analyses that lack granular data on key social determinants of health, including insurance status and geographic factors.5,8,12,13 Importantly, few studies have used validated measures of financial burden or distress or specifically examined patients undergoing LT evaluation. A single-item screening tool for high financial burden—defined as spending ≥10% of OOP costs on health care—has been shown to be a sensitive screening tool for financial distress and toxicity among LT recipients.10 Among LT candidates, the downstream effects of high financial burden may influence important transplant outcomes and highlight vulnerabilities that could be addressed through targeted resource allocation. Given the potential implications for access to transplantation, adherence to care, and post-transplant outcomes, a focused study in this population is critically needed.In this U.S. multicenter cross-sectional study, we assessed the prevalence of high financial burden (≥10% of income spent on OOP medical costs) among adults referred for LT evaluation and examined its associations with adverse outcomes, including work productivity loss, financial distress, and financial toxicity (poor HRQOL).

    METHODS

    We analyzed data from the Patient and Caregiver Evaluation: Assessing the impact of financial burden on outcomes in LT candidates (PACE-LT) study. The PACE-LT study is a multicenter, observational cohort study of adults undergoing LT evaluation. Patients were included if they were (1) adult (≥18 years of age) LT candidates or undergoing LT evaluation and (2) able to communicate and respond to questionnaires in English or Spanish. Patients were excluded if they had a history of a solid organ transplant (other than LT), a history of advanced malignancy [other than hepatocellular carcinoma (HCC)], or had an uncontrolled psychiatric illness or impaired cognition prohibiting informed consent.Patients were enrolled between May 2023 and April 2024. The patient cohort included a convenience sample of participants from 13 U.S. transplant centers (Supplemental Table S1, http://links.lww.com/HC9/C384). In all, 459 patients were enrolled. Of these, 6 patients were excluded due to missing financial burden data.Before study initiation, sites received a standardized REDCap database and completed a site initiation visit to ensure uniform data collection. Clinicians or trained research coordinators at each site enrolled patients and administered standardized questionnaires. Enrolled participants had up to 30 days after providing consent to complete questionnaires either in person, by telephone, or electronically. Study coordinators assisted phone respondents and participants with low reading or health literacy. No financial incentives were provided to participants.All research was conducted in accordance with both the Declarations of Helsinki and Istanbul. Study participants provided informed consent, and the Institutional Review Board at each participating site approved this study, which adhered to the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines.14Clinical information, including etiology of liver disease, presence of HCC, Model for End-stage Liver Disease—Sodium (MELD-Na) at enrollment, hepatic decompensation history [ascites, hepatic encephalopathy (HE) and variceal bleeding], tobacco use, alcohol use, history of transjugular intra-hepatic portosystemic shunt, coexisting medical conditions (diabetes, coronary artery disease, stroke, chronic obstructive pulmonary disease, chronic kidney disease, renal replacement therapy, obesity, non-dermatological malignancy, depression and anxiety), and insurance status was abstracted by trained study team members. Patients provided age, sex, race, ethnicity, marital status, educational attainment, annual household income, and employment status.The National Area Deprivation Index (ADI) was used to define patients’ neighborhood socioeconomic status based on a patient’s zip code. ADI is a composite metric that reflects neighborhood-level disadvantage and incorporates factors such as income, education, employment, and housing quality to evaluate the impact of social determinants on health outcomes.15 ADI scores range from 0 to 100, with 0 representing the least disadvantaged and 100 the most disadvantaged. Patients were categorized by ADI quintiles (Q1–Q5) using the 2020 ADI dataset.To assess financial burden and distress among LT candidates, a 25-item survey was used, incorporating 21 items from a health insurance sub-analysis within the Childhood Cancer Survivors Study and 4 items from a medication tradeoffs survey.16–19 (Supplemental Table S2, http://links.lww.com/HC9/C384) The Childhood Cancer Survivors Study draws from survey items developed by the National Health Interview Survey and Medical Expenditure Panel Survey, which have been validated in the general U.S. population to evaluate financial hardship among cancer survivors.20,21 Survey items were selected based on a previously established framework for financial burden, distress, and toxicity in CLD and in adult LT recipients.8,10The financial burden associated with OOP medical expenses was evaluated using a single-item measure: “In the past year, have you spent more than 10% of your income on medical expenses?”.10 A “yes” response indicated a high financial burden. This percentage was selected as OOP expenditures exceeding 10% of household income have been identified as an indicator of underinsurance and associated with increased financial distress in the general population, among adults with cancer, and among adult LT recipients.10,22–25 Furthermore, this one-question instrument provides a pragmatic way to identify participants with financial burden without increasing survey fatigue.Financial distress was characterized across 3 domains—material, behavioral, and psychological.8,10,26–30 Material financial distress (ie, tangible consequences of financial burden) was assessed using 5 items inquiring whether, in the past year, patients had to: (1) withdraw money from savings; (2) sell property or possessions; (3) take out a home mortgage or loan; (4) incur credit card debt; or (5) file for bankruptcy. Behavioral financial distress (ie, maladaptive coping strategies used to manage financial burden) was evaluated through 18 items assessing whether patients had: (1) increased support-seeking behaviors (eg, borrowing money and working more); (2) made tradeoffs related to their health care (eg, delaying or foregoing care); or (3) made tradeoffs involving basic necessities (eg, food, heating, or rent) due to medical expenses. Psychological financial distress (ie, worry due to financial burden) was measured using a single item asking whether patients worried about needing to file for bankruptcy due to medical costs.Health-related quality of life was assessed using the EuroQol EQ-5D-5L instrument. This tool consists of 2 components: the EQ-5D descriptive system, which evaluates 5 domains—mobility, self-care, usual activities, pain/discomfort, and anxiety/depression—and the EQ visual analog scale (EQ-5D VAS).31 Each EQ-5D dimension is scored on a scale from 1 to 5: 1 = no problems to 5 = extreme problems or inability to perform the activity.32 The 5 dimensions are combined to generate a health state, which is then converted into a single utility score (EQ-5D Index) using the U.S. EQ-5D-5L value set, reflecting population-based preferences for HRQOL.33,34 EQ-5D Index scores range from −0.573 (worst health state) to 1 (best health state).The EQ-5D VAS captures patients’ self-rated health on a 0–100 scale, where 0 represents “the worst health you can imagine” and 100 represents “the best health you can imagine.” The EQ-5D-5L has been validated in both LT candidates and recipients.35 The established minimal clinically important differences for the U.S. EQ-5D Index and EQ-VAS are 0.074 and 7 points, respectively.36,37The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Version 2.0 (WPAI:SHP V2.0)38 was used to assess the impact of health problems on work-related productivity and non-work-related activity impairment over the past 7 days. Domains assessed included absenteeism (work hours missed of total work hours), presenteeism (reduced effectiveness while working), daily activity impairment (impairment in daily activities other than work), and overall work productivity (combined absenteeism and presenteeism). This questionnaire was tailored to liver disease by substituting “health problems” in the general questionnaire with “liver disease.” It includes 6 items evaluating employment status, hours of work missed due to liver disease or other reasons, and hours worked. The impact of liver disease on work productivity and daily activities is measured using a visual analog scale from 0 (no effect) to 10 (completely prevented).We calculated frequencies with proportions for categorical sociodemographic and clinical characteristics and survey scores and means with standard deviations or medians with interquartile range for continuous variables, stratified by the explanatory variable of interest—patient-reported financial burden level (high: OOP costs ≥10% of household income, low: <10% or a response of “don’t know”). Additional sensitivity analysis was performed after exclusion of patients who responded “don’t know” to the patient-reported financial burden question. To compare the 2 groups, we used independent t tests, chi-squared, or Fisher’s exact tests, as appropriate.Study outcomes included work productivity loss, financial distress, and HRQOL. We used multivariable logistic and linear regression models to examine associations between financial burden and (1) material, behavioral, and psychological financial distress; (2) HRQOL as measured using the EQ-5D index (both total scores and individual domain scores) and EQ-5D VAS. These adjusted models included the following covariates selected a priori: income (≥$50K vs. <$50K), age, gender, race, ethnicity, education, marital status, insurance, comorbidities, transplant indication, current employment status, HCC, HE, ascites, and ADI quintile.39–47 We found no evidence of multicollinearity among financial burden, each individual financial distress metric, and ADI (all individual variance inflation factor values were <2.5 and all tolerance levels were >0.4). We reported odds ratios and regression coefficients and their 95% confidence intervals (CIs). Only observed survey data were used in analyses; no imputation was performed. The significance level was set at 0.05 without adjustment for multiple comparisons due to the hypothesis-generating nature of the analyses. All statistical analyses were conducted using SAS 9.4.

    RESULTS

    A total of 453 patients were included across 13 U.S. sites. At enrollment, 165 (36.4%) patients were listed for LT, and 288 (63.6%) were under evaluation for LT. Baseline characteristics are shown in Table 1. Patients undergoing LT evaluation had a median age of 58.7 years (IQR 49.7–64.7). The cohort was predominantly male (58.9%) and White (81.5%), with 22.1% identifying as Hispanic or Latino/a/x. A total of 59.4% were married or living with a partner, and 43.7% had a high school education or less. Most participants were not employed (72.4%). Nearly half (43.9%) reported an annual household income below $50,000. Median area deprivation index was 38.0 (IQR 24.0–61.0).Demographic and clinical characteristics of adult patients undergoing liver transplant evaluation with high versus low out-of-pocket medical costsp-value <0.05.Comorbid conditions: type II diabetes, coronary artery disease, congestive heart failure, stroke, chronic obstructive pulmonary disease, chronic kidney disease (not on renal replacement therapy), and end-stage renal disease (on renal replacement therapy).Abbreviations: AIH, autoimmune-related hepatitis; GED, General Educational Development; IQR, interquartile range; LT, liver transplantation; MASLD, metabolic dysfunction–associated steatotic liver disease; MELD-Na, Model for End-stage Liver Disease—Sodium; MetALD, MASLD + alcohol-associated liver disease; OOP, out of pocket; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; VA, Veterans Affairs.The leading indications for LT were alcohol-associated liver disease (43.0%) and metabolic dysfunction–associated steatotic liver disease (MASLD, 26.3%). The median MELD-Na score at the time of evaluation was 16 (IQR 11–21). Most patients had decompensated cirrhosis (85.7%), and 21.3% had HCC. In all, 49.0% had one or more comorbid conditions. Approximately a quarter of patients had diagnosed depression (25.4%) and anxiety (26.7%). Private insurance was most common (63.8%), followed by Medicaid (18.3%), Medicare (10.8%), multiple public insurance types (5.5%), Veterans Affairs (0.2%), and other/unknown (1.3%).Overall, 23.6% (107/453) of participants reported spending more than 10% of their household income on OOP medical expenses (high financial burden). In unadjusted models, recipients experiencing high financial burden were more likely to have a lower income (p=0.004) and a diagnosis of anxiety (34.6% vs. 24.3%; p=0.045) than those with low financial burden. In adjusted models, there were no significant differences in any sociodemographic or clinical characteristics between recipients reporting high versus low financial burden.Figure 1 demonstrates the prevalence of material, behavioral, and psychological financial distress among adults referred for LT based on their financial burden status.Financial distress among adult liver transplant candidates; *p<0.05.LT candidates with high financial burden were significantly more likely to report loss of savings (72% vs. 30%, p<0.001), having experienced medical debt (38% vs. 18%, p<0.001), support-seeking (49% vs. 23%, p<0.001), having delayed or foregone medical care (66% vs. 34%, p<0.001), and being unable to pay for basic necessities (29% vs. 11%, p<0.001). LT candidates with high financial burden were significantly more likely to experience material (77% vs. 36%, p<0.001), behavioral (75% vs. 44%, p<0.001), and psychological distress (16% vs. 5%, p<0.001).In adjusted analyses, high financial burden was significantly associated with problems paying for medical bills (aOR 6.12, 95% CI: 3.37–11.14), delayed or foregone healthcare (aOR 4.02, 95% CI: 2.30–7.02), inability to pay for basic necessities (aOR 4.76, 95% CI: 2.34–9.67), support seeking (aOR 4.30, 95% CI: 2.37–7.83), loss of savings or assets (aOR 4.79, 95% CI: 2.73–8.40) and having experienced medical debt/bankruptcy (aOR 2.92, 95% CI: 1.65–5.16) (Table 2). Patients reporting high financial burden had significantly higher adjusted odds of any behavioral distress (aOR 3.96, 95% CI: 2.17–7.22), any material distress (aOR 4.72, 95% CI: 2.64–8.45), and psychosocial distress (aOR 4.63, 95% CI: 1.95–10.98) (Table 2).Associations between high financial burden (medical out-of-pocket expenses ≥10% of income) and financial distress among adult liver transplant candidatesNote: Statistical significance values are bolded.Adjusted odds ratios represent the odds of reporting the outcome among those with high financial burden relative to the odds among those with low financial burden. Estimates are adjusted for: age, gender, race, ethnicity, education, marital status, income, insurance, comorbidities, transplant indication, hepatocellular carcinoma, employment, ascites, hepatic encephalopathy, and quintile of area deprivation index.Figure 2 shows WPAI scores among patients experiencing high versus a low financial burden. Activity impairment outside of work did not differ by financial burden, with both high-burden and low-burden groups reporting an average of 30.6% impairment—reflecting the extent to which their liver disease health impaired their daily functioning beyond their job responsibilities. Among participants who were currently employed (n=125, 27.6%), the mean productivity impairment over the preceding 7 days was as follows: absenteeism (time missed from work) was 21.7%, presenteeism (reduced performance while at work) was 31.7%, and overall work productivity loss was 39.6%. Among those who were currently employed, there were no significant differences in presenteeism, overall work impairment, or activity impairment outside of work between recipients with high versus low financial burden; however, patients reporting high financial burden were significantly more likely to report absenteeism (mean 34.1% vs. 16.9%; p=0.018).Work productivity and activity impairment (WPAI) according to financial burden status among adult liver transplant candidates; p<0.05.Table 3 presents the adjusted analyses examining the association of financial burden with HRQOL as measured using the EQ-5D Index and EQ-5D VAS scores.Associations between high financial burden (medical out-of-pocket expenses ≥10% of income) and health-related quality of life among adult liver transplant candidatesNote: Statistical significance values are bolded.Estimated regression coefficients represent (1) for categorical characteristics, the difference in mean outcome score between the stated sub-category and the reference sub-category, or (2) for continuous characteristics, the change in the mean outcome score for each one-unit increase in the continuous characteristic.Abbreviation: ADI, Area Deprivation Index.Patients reporting high financial burden had significantly lower EQ-5D VAS scores [54.4 (SD 22.9) vs. 62.5 (SD 22.7), p=0.002]. In adjusted analyses, high financial burden was not independently associated with EQ-5D VAS scores. This result was unchanged after sensitivity analysis in which patients who responded “don’t know” to the financial burden screening question were excluded. Female gender and higher ADI quintile were significantly associated with lower EQ-5D VAS scores on adjusted analyses.There were no significant differences in EQ-5D index scores based on financial burden status [high: 0.7 (SD: 0.2) vs. low: 0.8 (SD: 0.02); p=0.065]. In adjusted analyses, high financial burden was not independently associated with EQ-5D index scores. However, when a sensitivity analysis was performed in which patients who responded “don’t know” to the financial burden screening question were excluded, high financial burden was independently associated with lower EQ-5D index scores (p=0.046). Unemployed status and the presence of ascites were significantly associated with lower EQ-5D index scores on adjusted analyses.Individual EQ-5D domains were examined, and high financial burden was found to be associated with worse mobility and self-care scores (β: 0.23, 95% CI: 0.01–0.45, p=0.04 and β: 0.21, 95% CI: 0.04–0.38, p=0.02) (Supplemental Table S3, http://links.lww.com/HC9/C384).

    DISCUSSION

    In this large U.S. multicenter cohort of adults undergoing LT evaluation, 1 in 4 reported high financial burden, defined as spending 10% or higher of their OOP costs on their medical bills, and nearly 3 in 4 were unemployed. Among those who were employed, overall work productivity loss reached 40%. This burden was not only prevalent but deeply consequential. High financial burden was independently and strongly associated with behavioral financial distress (4 times higher odds of delayed or foregone medical care), material financial distress (nearly 5 times higher odds of being unable to pay for basic necessities and depletion of savings/assets), and psychological distress (nearly 4 times higher odds of financial anxiety related to medical costs). Although financial burden was not independently associated with HRQOL after accounting for key clinical and sociodemographic factors, its strong associations with multiple forms of financial distress and work productivity underscore its central importance. Taken together, these findings demonstrate that financial burden is not an ancillary concern for patients under evaluation for LT—it is a central, psychosocially and clinically relevant vulnerability associated with work productivity loss and financial distress. Financial distress represents an early, patient-centered, and actionable mediator linking financial burden to downstream outcomes.Financial burden encompasses far more than the expenses themselves—it is tightly linked to financial distress, reflected in coping mechanisms driven by constrained resources that can threaten transplant candidacy, disease stability, and medication adherence. Prior studies in CLD populations have shown that cost-related nonadherence contributes to worsening ascites, HE, and hospitalizations, which have the potential to impact LT evaluation and candidacy.6 Notably, although we observed profound financial burden and distress, we did not find any socioeconomic or clinical characteristics that independently predicted high financial burden after adjustment. This suggests that financial vulnerability among LT candidates is widespread and not limited to traditionally recognized high-risk groups. At the same time, structural inequities—including but not limited to differential access to public services, healthcare, and transplant referral pathways—likely shape how financial burden is experienced and managed, particularly among underrepresented populations. These factors may amplify financial burden and distress in ways not captured by traditional sociodemographic variables, underscoring the need for more equity-focused approaches to screening and intervention. Collectively, these findings suggest that financial burden and distress are key determinants of health in LT candidates, with the potential to impact disease stability, candidacy, and outcomes.Unemployment and impaired work productivity emerged as major challenges for patients referred for LT, with nearly three-quarters of respondents unemployed despite most being of working age. This far exceeds prior estimates, showing that roughly 30% of individuals with CLD are unable to work due to illness or disability.40,48,49 Our findings underscore the uniquely vulnerable employment circumstances of LT candidates and extend previous work by directly linking unemployment, financial burden, and downstream financial distress in a nationally representative cohort. Among those who remain employed, a high financial burden is associated with substantial absenteeism. Patients missed more than one-third of working time because of their liver disease—and that likely accelerates wage loss, threatens job stability, and compounds financial strain. This cascade—in which liver disease drives unemployment, financial strain heightens distress, and financial distress undermines liver-related care—represents a key, actionable target for intervention.Beyond the economic and employment impacts, adults with high financial burden initially showed significantly lower EQ-5D scores, indicating poorer HRQOL. However, after adjusting for key clinical and sociodemographic factors, high financial burden was not independently associated with EQ-5D scores. One hypothesis is that the initial association between high financial burden and lower HRQOL may be largely explained by underlying clinical and sociodemographic factors, rather than a direct effect of financial burden itself, which is substantiated by the fact that ascites is associated with lower EQ-5D. When considering the total EQ-5D score, the lack of association after adjusting for relevant clinical and sociodemographic risk factors may reflect financial burden that has not yet resulted in overt financial distress, such as early cost-related tradeoffs or delayed and forgone care, that may precede measurable declines in HRQOL. Of note, when subdomains were examined, high financial burden was associated with worse mobility and self-care scores, suggesting that these EQ-5D domains are sensitive to financial burden. Impairments in mobility and self-care may contribute to a higher financial burden by limiting the ability to work, increasing reliance on caregivers, and amplifying healthcare utilization and OOP costs among LT candidates.Our findings carry important implications for transplant practice. Financial burden and unemployment are common before listing and are strongly associated with care disruption (eg, medication nonadherence and missed appointments) and worse perceived health. Financial distress may represent an early, patient-centered manifestation of financial burden that precedes downstream consequences. Accordingly, screening for financial distress during the transplant evaluation and waitlisting process offers a potential window for early intervention to mitigate longer-term adverse health outcomes. Incorporating brief, feasible screening tools, such as a single-item measure, can help identify high-risk individuals who may benefit from more intensive interventions.Screening for financial burden and distress is particularly important for LT candidates, as these compounding stressors are being scrutinized when determining candidacy for transplantation and could be viewed unfavorably during transplant candidate evaluation. Yet, patient-centered financial screening is not routinely or systematically integrated into most evaluations. Our results substantiate that financial burden is a marker for negative outcomes, including financial distress and toxicity. Importantly, this was identified using a single-item financial burden screen validated in LT recipients that is feasible to administer during the evaluation process to identify high-risk individuals.10 Importantly, screening should extend beyond perceived financial burden to include actionable indicators of financial distress, such as delayed and/or forgone care, which can lead to negative downstream consequences. These high-risk patients could then be targeted for interventions, including financial navigation, medication assistance programs, transportation support, disability advocacy, and employment counseling.Employment-focused interventions are also particularly compelling. Return to work after LT remains uncommon, occurring in <20% of LT recipients.50 This is especially true among patients who are unemployed pre-transplant. Pre-LT employment is one of the strongest predictors of post-LT workforce reintegration51. Interventions aimed at preserving employment before transplantation may therefore have durable financial and psychosocial benefits that extend well beyond the transplant itself. These strategies include: (1) aggressive symptom control to improve functional capacity, (2) structured vocational programs and employer engagement, and (3) policy-level protections that reduce work disincentives and promote reasonable workplace accommodations. Employment should be viewed not merely as a social outcome, but as a core component of transplant-related health equity.This study has several important strengths, including its large sample size, national multicenter design, and the use of validated survey instruments to assess financial distress, work productivity, and HRQOL. However, certain limitations should be acknowledged. First, the cross-sectional design precludes causal inference and does not capture how financial burden evolves over time or across transplant milestones. It remains unclear if financial burden, defined as spending >10% of one’s income on medical expenses, leads to the negative outcomes of financial distress and toxicity; however, our results substantiate that this is a useful marker of these important outcomes, which can easily be screened for at LT centers. Second, a single-item screening question was used to determine high financial burden rather than a psychometric scale. However, this approach enhances real-world feasibility. Third, while our survey instruments were developed and validated in large U.S. populations, they have not been specifically validated in CLD patients.11,20,21 Fourth, our cohort was predominantly White and limited to English-speaking and Spanish-speaking patients, potentially impacting generalizability to all linguistic, racial, and ethnic groups, as well as structurally marginalized populations who may experience even greater financial vulnerability. Lastly, our study population represents a convenience sample; while response rates were collected at most centers, they were unavailable at all, representing a study limitation. Furthermore, hard outcomes—including healthcare utilization, LT waitlist additions, and post-LT clinical outcomes—warrant further investigation.

    CONCLUSION

    This multicenter cohort study found that almost 1 in 4 patients referred for LT experience a high financial burden, which was significantly associated with delayed or foregone medical care, inability to meet basic needs, financial distress, impaired work productivity, and worse self-rated health. Importantly, financial distress may represent an early, patient-centered manifestation of financial burden that precedes these downstream consequences, highlighting a potential window for early identification and intervention through social workers and/or financial navigators to improve longer-term clinical outcomes. Notably, over 70% of these patients were unemployed despite the majority being of working age, and among those who were able to work, there was 40% work productivity loss. These findings establish financial burden as a core, psychosocially and clinically relevant vulnerability in transplant candidates—one that likely influences access to care, waitlist outcomes, and post-LT recovery. Routine screening and early, targeted intervention at the patient, health system, and policy levels represent critical next steps to mitigate financial toxicity and improve outcomes for patients with CLD.
    NUDr. Nneka Ufere
    Leading Voice

    Dr. Nneka Ufere

    Gastroenterology · Hepatology & Liver Transplantation
    Massachusetts General Hospital
    nneka